Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
about
Disappearing acts of ADAMTS13A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasmaNeutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse.Mechanisms of Autoantibody-Induced Pathology.Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.A New Classification System for IgG4 Autoantibodies.Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.Thrombotic thrombocytopenic purpuraThrombotic thrombocytopenic purpura
P2860
Q26783127-2F6B561F-57D5-4149-9BB4-78FD821C2552Q33416555-50875F98-2970-4105-A64A-57992E1024C3Q33418539-605A7BF2-5CF2-4A0F-BE7D-E8E30E0A1985Q33423510-9171FD39-FF27-4364-AD01-54849EC34F20Q33425638-2EB43529-510D-4075-8A2F-2062957F2FA8Q33426377-C668C509-DE3F-4DD6-BB2B-697C72E8DD68Q33427651-AEBC9F3F-19EF-4E16-ADCE-59DE9846976DQ33434516-E21EB442-89A4-475F-A420-070C3AD3D777Q33740580-DA77209F-F858-40EB-B2F2-A87DFDC5DE70Q42722751-69904225-5A65-49A8-ACB2-A4667A9878FCQ47128233-C8CE3E7A-DAC3-4FC6-A694-98162BD4C7C3Q50327901-3E28B24C-39E1-478F-8023-305470B9594FQ52345676-D839EA48-9E78-4B91-A30F-DBBC2AC8683CQ52576561-3FF3914E-D008-4ECF-95A0-0E5ED40D8A1CQ55287154-D9D625DC-A6F6-46DC-80E5-71D8D9F3DAB4Q57379903-648CA20B-1D5C-4EB5-8993-1F8D7FDFFEF2Q58767790-3FAE7F5E-F95C-422C-AB2A-7A194E77051B
P2860
Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@ast
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@en
type
label
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@ast
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@en
prefLabel
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@ast
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P1433
P1476
Persistence of circulating ADA ...... otic thrombocytopenic purpura.
@en
P2093
Bernadette Gruber
Caroline Cromwell
Claudine Caron
Friedrich Scheiflinger
Hanspeter Rottensteiner
Kristina Palavra
Louis Aledort
Paul Knöbl
Peter L Turecek
Silvia Ferrari
P2860
P304
P356
10.3324/HAEMATOL.2013.094151
P577
2013-11-15T00:00:00Z